HLB Panagene Co., Ltd. manufactures and sells genetic diagnostic products in South Korea and internationally. It offers PANAMutyper, which detects small amount of mutation with high sensitivity and genotypes multiple mutations for oncology liquid biopsy; PNAClamp, a PNA-based PCR clamping that detects and amplifies only the mutated target DNA sequence for oncology tissue biopsy; PANA RealTyper, a PNA probe-based fluorescence melting curve analysis tool that detects mutation and distinguishes multiple SNPs adjacent for infectious diseases; PANA qPCR, a tool used for multiplexing, allelic discrimination experiments, and quantitative analysis; and PNA, an artificially created DNA analogue. The company was formerly known as Panagene Inc. and changed its name to HLB Panagene Co., Ltd. in August 2023. HLB Panagene Co., Ltd. was founded in 1976 and is headquartered in Daejeon, South Korea.
Metrics to compare | 046210 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship046210PeersSector | |
|---|---|---|---|---|
P/E Ratio | 48.8x | −11.9x | −0.6x | |
PEG Ratio | 0.43 | −0.09 | 0.00 | |
Price/Book | 1.1x | 3.5x | 2.6x | |
Price / LTM Sales | 5.7x | 6.4x | 3.4x | |
Upside (Analyst Target) | - | 33.9% | 44.4% | |
Fair Value Upside | Unlock | 11.0% | 6.1% | Unlock |